State Board of Administration of Florida Retirement System trimmed its holdings in Innoviva Inc (NASDAQ:INVA) by 19.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 154,556 shares of the biotechnology company’s stock after selling 36,907 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Innoviva were worth $2,697,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of INVA. SG Americas Securities LLC acquired a new position in Innoviva during the fourth quarter valued at approximately $5,208,000. Rhumbline Advisers raised its stake in Innoviva by 19.2% in the fourth quarter. Rhumbline Advisers now owns 197,241 shares of the biotechnology company’s stock valued at $3,442,000 after buying an additional 31,815 shares during the period. Wedge Capital Management L L P NC raised its stake in Innoviva by 24.5% in the fourth quarter. Wedge Capital Management L L P NC now owns 44,430 shares of the biotechnology company’s stock valued at $775,000 after buying an additional 8,741 shares during the period. Cordatus Wealth Management LLC bought a new stake in Innoviva in the fourth quarter valued at approximately $736,000. Finally, Ackerman Capital Advisors LLC bought a new stake in Innoviva in the fourth quarter valued at approximately $22,000,000. 75.77% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:INVA traded up $0.09 on Monday, hitting $14.82. The company’s stock had a trading volume of 1,228,854 shares, compared to its average volume of 1,488,338. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of 4.20 and a beta of 1.89. Innoviva Inc has a one year low of $13.26 and a one year high of $20.54.

Several analysts have issued reports on the company. Zacks Investment Research lowered Innoviva from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. BidaskClub lowered Innoviva from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 2nd. Finally, ValuEngine lowered Innoviva from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $16.50.

ILLEGAL ACTIVITY WARNING: This article was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://theolympiareport.com/2019/02/18/innoviva-inc-inva-shares-sold-by-state-board-of-administration-of-florida-retirement-system.html.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI).

Read More: How Investors Can Profit from Options Trading

Want to see what other hedge funds are holding INVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Innoviva Inc (NASDAQ:INVA).

Institutional Ownership by Quarter for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.